Sign In
Buy INSM
$102.15
+3.55 (+3.60%)
At Close: Jun 23, 2026
Insmed Appoints Samuele Butera as Senior Vice President, General Manager, Global Respiratory
07:00am, Tuesday, 23'rd Jun 2026
BRIDGEWATER, N.J., June 23, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform
The Qs Shift Gears: Nasdaq 100 Rebalances While SpaceX Looms
02:19pm, Monday, 22'nd Jun 2026
The Nasdaq 100 implemented its June quarterly rebalance, which shifts the tide for “the Qs.” Namely, the Invesco QQQ Trust (QQQ) and its cost-efficient sibling, the Invesco Nasdaq 100 ETF (QQQM).
Insmed: Extensive Phase 3 TPIP Program And Revenue Growth In Q1 2026, Strong Buy
07:30am, Monday, 22'nd Jun 2026
Insmed is maintained at "Strong Buy" due to robust pipeline progress and expanding commercial execution. INSM's key catalysts include ARIKAYCE's sNDA submission for 1st-line MAC Lung Disease in H2 202
Nasdaq-100 Index® June 2026 Quarterly Changes
08:00pm, Thursday, 11'th Jun 2026
NEW YORK, June 11, 2026 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the results of the June 2026 quarterly rebalance of the Nasdaq-100 Index (NDX), which will become effective prior to m
Insmed Incorporated (INSM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
01:22pm, Tuesday, 09'th Jun 2026
Insmed Incorporated (INSM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
07:00am, Thursday, 04'th Jun 2026
BRIDGEWATER, N.J., June 4, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform
Insmed to Present at the 2026 Goldman Sachs Annual Global Healthcare Conference
07:00am, Wednesday, 27'th May 2026
BRIDGEWATER, N.J., May 27, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform
Insmed Incorporated (INSM) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
12:50pm, Wednesday, 20'th May 2026
Insmed Incorporated (INSM) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Insmed CEO Defends BRINSUPRI Launch as Sales Surge, TPIP Pipeline Gains Focus
03:04am, Monday, 18'th May 2026
Insmed NASDAQ: INSM Chair and CEO Will Lewis said the company remains confident in the launch trajectory of BRINSUPRI, despite investor concerns over discontinuation rates that followed the company's
Insmed Incorporated (INSM) Presents at Bank of America Global Healthcare Conference 2026 Transcript
07:20pm, Tuesday, 12'th May 2026
Insmed Incorporated (INSM) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Insmed's Q1 Earnings Beat, Sales Miss Estimates, Stock Tanks 23%
11:06am, Friday, 08'th May 2026
INSM stock plunges 23% after Q1 sales miss estimates despite 230% revenue growth and strong Brinsupri uptake.
Insmed Incorporated (INSM) Q1 2026 Earnings Call Transcript
02:51pm, Thursday, 07'th May 2026
Insmed Incorporated (INSM) Q1 2026 Earnings Call Transcript
Insmed Tanks On Its Most Important Launch; Why Analysts Remain Bullish
11:03am, Thursday, 07'th May 2026
Insmed stock tanked Thursday after its new lung drug, Brinsupri, missed elevated buy-side expectations, though beat sell-side views.
Insmed (INSM) Reports Q1 Loss, Misses Revenue Estimates
09:56am, Thursday, 07'th May 2026
Insmed (INSM) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.9. This compares to a loss of $1.42 per share a year ago.
Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update
07:00am, Thursday, 07'th May 2026
— Total Company Revenues of $306.0 Million for the First Quarter of 2026— —BRINSUPRI ® (brensocatib) Revenues of $207.9 Million for the First Quarter of 2026, Reflecting 44% Growth Over the Fou
